Novo says CagriSema tops Lilly rival in diabetes patients for weight loss
- Posted on September 21, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Novo says CagriSema tops Lilly rival in diabetes patients for weight loss
Sept 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly's rival drug. It has been seen as a successor to Novo's weight loss drug, Wegovy, which faces patent expiries after 2030. CagriSema is a weekly injection combining
